* Augment bone graft shows lower bone fusion vs autograft * Shares down 16 pct in after-hours trade
Oct 13 (Reuters) - BioMimetic Therapeutics Inc said its experimental product to help bone growth showed lower rate of bone-fusion compared to the standard-of-care in a late-stage trial, sending shares down 16 percent.
On an intent-to-treat population, 24-week fusion rates were 57.9 percent for patients receiving the product Augment and 60.4 percent for patients on autograft.
Achieving bone fusion was defined by 50 percent or greater bone bridging at 24 weeks in the study, the company said in a statement.
The company's Augment bone graft was being tested for use in hindfoot and ankle fusion surgery to treat chronic pain.
Shares of the company were down 16 percent to $10.90 in trading after the bell. They closed at $12.97 Tuesday on Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by Aradhana Aravindan) Keywords: BIOMIMETIC/ (krishnakali.sengupta@thomsonreuters.com; within U.S +1 646 223 8780; outside U.S +91 80 4135 5800; Reuters Messaging: krishnakali.sengupta.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Oct 13 (Reuters) - BioMimetic Therapeutics Inc said its experimental product to help bone growth showed lower rate of bone-fusion compared to the standard-of-care in a late-stage trial, sending shares down 16 percent.
On an intent-to-treat population, 24-week fusion rates were 57.9 percent for patients receiving the product Augment and 60.4 percent for patients on autograft.
Achieving bone fusion was defined by 50 percent or greater bone bridging at 24 weeks in the study, the company said in a statement.
The company's Augment bone graft was being tested for use in hindfoot and ankle fusion surgery to treat chronic pain.
Shares of the company were down 16 percent to $10.90 in trading after the bell. They closed at $12.97 Tuesday on Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by Aradhana Aravindan) Keywords: BIOMIMETIC/ (krishnakali.sengupta@thomsonreuters.com; within U.S +1 646 223 8780; outside U.S +91 80 4135 5800; Reuters Messaging: krishnakali.sengupta.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.